Showing 1281-1290 of 1484 results for "".
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- EU Authorizes AstraZeneca’s COVID-19 Vaccine Amid Supply Disputehttps://modernod.com/news/eu-authorizes-astrazenecas-covid-19-vaccine-amid-supply-dispute/2478816/The European Commission on Friday granted a conditional marketing authorization to AstraZeneca and the University of Oxford’s AZD1222 for people aged 18 years and older, making it the third COVID-19 vaccine authorized in the EU, following Pfizer and BioNTech’s vaccine Comirnaty, as we
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclandahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-treatment-roclanda/2478740/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monoth
- Moderna’s COVID-19 Vaccine Becomes Second to Nab EU Authorizationhttps://modernod.com/news/modernas-covid-19-vaccine-becomes-second-to-nab-eu-authorization/2478725/The European Commission on Wednesday granted a conditional marketing authorization for Moderna’s COVID‑19 vaccine mRNA-1273, making it the second coronavirus vaccine authorized in the EU. The decision comes hours after the European Medicines Agency (EMA) had recommended authorizing mRNA-127
- Norlase Receives CE Mark Approval for LION Green Laser Systemhttps://modernod.com/news/norlase-receives-ce-mark-approval-for-lion-green-laser-system/2478718/Norlase announced that it has been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase’s compact laser technology into one device. With LION’s untethered and portable design, physicians can move freely between treatm
- EU Authorizes First COVID-19 Vaccine With Pfizer, BioNTech’s Comirnatyhttps://modernod.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/The European Commission on Monday granted a conditional marketing authorization to Pfizer and BioNTech’s coronavirus vaccine BNT162b2, which will go by the name Comirnaty, with the decision coming mere hours after the Committee for Medicinal Products for Human Use (CHMP) gave its backing fo
- Vaccine Rollout On Track, Expect 300M Doses Through March: Fedshttps://modernod.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/If the initial success of the Pfizer-BioNTech rollout continues, and emergency use authorization (EAU) is granted to Moderna and Johnson & Johnson vaccines in development, Operation Warp Speed officials expect to have 300 million doses of COVID-19 vaccines to distribute across the United Stat
- UK Authorizes Use of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/uk-authorizes-use-of-pfizer-biontechs-covid-19-vaccine/2478614/The UK government said Wednesday that it accepted a recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to grant temporary authorization of Pfizer and BioNTech’s mRNA-based COVID-19 vaccine BNT162b2. A Department of Health and Social Care spokesperson said 
- FDA Authorizes Lilly’s Antibody Therapy Bamlanivimab for Recently Diagnosed COVID-19https://modernod.com/news/fda-authorises-lillys-antibody-therapy-bamlanivimab-for-recently-diagnosed-covid-19/2478512/Eli Lilly announced Monday that the FDA has granted its emergency-use authorization (EUA) request for the investigational neutralizing antibody bamlanivimab. The AbCellera-partnered therapy, also known as LY-CoV555, is authorized to treat recently diagnosed, mild-to-moderate COVID-19 in patients